Proprietary exosome engineering platform developing multi-target therapeutics for autoimmune diseases including rheumatoid arthritis, Crohn's, and psoriasis.
Entelexo is developing a novel class of engineered exosome-based therapeutics for autoimmune diseases through a proprietary rational engineering platform. Their exosomes are designed to communicate with multiple specific diseased cell types simultaneously, addressing the multi-pathway complexity of conditions like Rheumatoid Arthritis, Crohn's Disease, and Psoriasis that existing single-target therapies cannot fully treat. The company has an initial pipeline of product candidates de-risked with human cell immunoassays and is preparing for pre-IND FDA studies. Entelexo is a product of Entelexo Biotherapeutics.